Conference Coverage
Conference Coverage
Postmenopausal hot flashes cut by 93% with novel nonhormonal treatment
The investigational neurokinin 3 receptor antagonist fezolinetant successfully and safely reduced hot flushes in postmenopausal women.
Conference Coverage
In PCOS, too much sitting means higher glucose levels
ORLANDO – Prolonged sitting time was associated with higher blood glucose levels in women with polycystic ovary syndrome.
Conference Coverage
How to reduce the open hysterectomy rate
SAN ANTONIO – Funded proctoring makes a big difference in encouraging minimally invasive hysterectomy.
Conference Coverage
VIDEO: Stroke risk in women deserves greater attention
BOSTON – Texas neurologist Louise McCullough, MD, PhD, is determined to help women live longer by urging neurologists to focus on the unique risks...
Conference Coverage
Liposomal bupivacaine cut need for opioids after gyn surgery
If you’re worried about opioid addiction, liposomal bupivacaine could be an option for pain control after outpatient gynecologic surgery.
Conference Coverage
Avoid hysterectomy in POP repairs
SAN ANTONIO – New guidelines from the Society of Gynecologic Surgeons are aimed at aiding surgeons as they consider the role of hysterectomy for...
Conference Coverage
Neurokinin receptor antagonist nearly halves hot flashes
ORLANDO – The novel approach reduced hot flashes without the need for estrogen in a phase II trial.
Conference Coverage
MedPAC: Medicare Part B drug payment cuts, shared savings could save $5 billion
Reducing the amount physicians are paid for drugs administered in their offices and introducing shared savings could save Medicare up to $5...
Conference Coverage
Infants’ head circumference larger with PCOS moms on metformin
Infants born to women with PCOS who took metformin during pregnancy have larger heads than those born to women who took placebo.
Conference Coverage
NET can benefit breast cancer patients with delayed surgery
For breast cancer patients whose surgery is delayed, a course of neoadjuvant therapy may be beneficial, but the effectiveness depends on the...
Conference Coverage
Atezolizumab improved survival in triple-negative breast cancer
In a phase I trial, the immunotherapy agent atezolizumab improved survival in triple-negative breast cancer.